arrow
L

Lorenzo Antonuzzo

University of Florence
H指数:43
被引数:7,691

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategies

曲妥珠单抗德鲁替康在HER2表达性尿路上皮癌中的应用:当前证据、生物标志物挑战及未来治疗策略

2026-11-050
OA
Real world outcomes of perioperative FLOT in an Italian cohort of resectable gastric cancer: long term follow-up of prospective observational Real-FLOT study

可切除胃癌意大利队列中围手术期FLOT的长期随访真实世界结果:前瞻性观察性Real-FLOT研究

2026-09-170
OAAI
Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

奥拉帕利在全球真实世界中对具有同源重组修复改变的转移性去势抵抗性前列腺癌患者的疗效

2026-08-310
OAAI
Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention

开启高风险生化复发前列腺癌的新时代:重新定义早期系统性干预

2026-08-250
OAAI
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)

HERO评分在恩沃利单抗治疗的转移性尿路上皮癌中的真实世界预后评估(ARON-2EV研究)

2026-07-010
OAAI
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial

一线纳武利尤单抗联合FOLFOXIRI/贝伐珠单抗治疗RAS/BRAF突变型晚期结直肠癌:NIVACOR II期试验的疗效、安全性和生物标志物发现

2026-03-250
OAAI
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial

Antonuzzo, L.; Lavacchi, D.; Spada, F.; Marconcini, R.; Gelsomino, F.; Amoroso, V.; Cosso, F.; Pellegrini, E.; Scolari, F.; Sparano, C.; 等. 依维莫司作为晚期神经内分泌肿瘤的维持疗法:来自MAVERIC II期试验的结果. Oncologist 2026, 31, oyaf432. [Google Scholar] [CrossRef] [PubMed]

2026-03-010
PRE
Molecular profiling and matched targeted treatment in cholangiocarcinoma: results from the Italian dataset (ANITA)

胆管癌的分子谱分析和匹配的靶向治疗: 来自意大利数据集 (ANITA) 的结果

2025-12-270
OAAI
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)

Avelumab维持治疗在晚期尿路上皮癌中的真实世界有效性:来自意大利多中心MALVA研究(Meet-URO 25)的结果

2025-12-010
PRE
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study

同源重组修复基因检测变量及前列腺癌患者的诊断路径:一项多中心队列研究

2025-12-010
PRE
Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management

神经内分泌肿瘤骨转移:一项关于自然史和管理的意大利全国性调查结果

2025-11-180
OAAI